Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model

Sarah Brem, Betty Tyler, Khan Li, Gustavo Pradilla, Federico Legnani, Justin Caplan, Henry Brem

Research output: Contribution to journalArticle

Abstract

Purpose: Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model. Methods: Temozolomide was incorporated into biodegradable polymers and the active drug was released over 80 h. Intracranial toxicity was assessed in F344 rats and a maximally tolerated dose was not achieved. Results: In vivo drug biodistribution demonstrated that intracranial concentrations of TMZ increased threefold compared with orally delivered TMZ. In a rodent glioma model, animals treated with a single TMZ polymer (50% w/w) had a median survival of 28 days (P <0.001 vs. controls, P <0.001 vs. oral treatment), whereas animals treated with oral TMZ had a median survival of 22 days compared to control animals (median survival of 13 days). Animals treated with two TMZ polymers (50% w/w) had a median survival of 92 days (P <0.001 vs. controls, P <0.001 vs. oral treatment). The percentage of long-term survivors (LTS) for groups receiving intracranial TMZ ranged from 25 to 37.5%; there were no LTS with oral TMZ treatment. Animals treated with radiation therapy (XRT) and intracranial TMZ (median survival not reached, LTS = 87.5%) demonstrated improved survival compared to those with intracranial TMZ alone (median survival, 41 days; LTS = 37.5%), or oral TMZ and XRT (median survival, 43 days, LTS = 38.9%). Conclusions: The survival of tumor-bearing animals was improved with local delivery of TMZ compared with systemic administration. XRT in combination with intracranial TMZ did not cause additional toxicity and prolonged the survival even further.

Original languageEnglish
Pages (from-to)643-650
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume60
Issue number5
DOIs
Publication statusPublished - Oct 2007

Fingerprint

temozolomide
Biodegradable polymers
Glioma
Oral Administration
Rodentia
Polymers
Animals
Survival
Survivors
Toxicity

Keywords

  • 9L gliosarcoma
  • Local delivery
  • Polymer
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. / Brem, Sarah; Tyler, Betty; Li, Khan; Pradilla, Gustavo; Legnani, Federico; Caplan, Justin; Brem, Henry.

In: Cancer Chemotherapy and Pharmacology, Vol. 60, No. 5, 10.2007, p. 643-650.

Research output: Contribution to journalArticle

Brem, Sarah ; Tyler, Betty ; Li, Khan ; Pradilla, Gustavo ; Legnani, Federico ; Caplan, Justin ; Brem, Henry. / Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. In: Cancer Chemotherapy and Pharmacology. 2007 ; Vol. 60, No. 5. pp. 643-650.
@article{6f1790a55f3843bf92633c64d066cd94,
title = "Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model",
abstract = "Purpose: Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model. Methods: Temozolomide was incorporated into biodegradable polymers and the active drug was released over 80 h. Intracranial toxicity was assessed in F344 rats and a maximally tolerated dose was not achieved. Results: In vivo drug biodistribution demonstrated that intracranial concentrations of TMZ increased threefold compared with orally delivered TMZ. In a rodent glioma model, animals treated with a single TMZ polymer (50{\%} w/w) had a median survival of 28 days (P <0.001 vs. controls, P <0.001 vs. oral treatment), whereas animals treated with oral TMZ had a median survival of 22 days compared to control animals (median survival of 13 days). Animals treated with two TMZ polymers (50{\%} w/w) had a median survival of 92 days (P <0.001 vs. controls, P <0.001 vs. oral treatment). The percentage of long-term survivors (LTS) for groups receiving intracranial TMZ ranged from 25 to 37.5{\%}; there were no LTS with oral TMZ treatment. Animals treated with radiation therapy (XRT) and intracranial TMZ (median survival not reached, LTS = 87.5{\%}) demonstrated improved survival compared to those with intracranial TMZ alone (median survival, 41 days; LTS = 37.5{\%}), or oral TMZ and XRT (median survival, 43 days, LTS = 38.9{\%}). Conclusions: The survival of tumor-bearing animals was improved with local delivery of TMZ compared with systemic administration. XRT in combination with intracranial TMZ did not cause additional toxicity and prolonged the survival even further.",
keywords = "9L gliosarcoma, Local delivery, Polymer, Temozolomide",
author = "Sarah Brem and Betty Tyler and Khan Li and Gustavo Pradilla and Federico Legnani and Justin Caplan and Henry Brem",
year = "2007",
month = "10",
doi = "10.1007/s00280-006-0407-2",
language = "English",
volume = "60",
pages = "643--650",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model

AU - Brem, Sarah

AU - Tyler, Betty

AU - Li, Khan

AU - Pradilla, Gustavo

AU - Legnani, Federico

AU - Caplan, Justin

AU - Brem, Henry

PY - 2007/10

Y1 - 2007/10

N2 - Purpose: Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model. Methods: Temozolomide was incorporated into biodegradable polymers and the active drug was released over 80 h. Intracranial toxicity was assessed in F344 rats and a maximally tolerated dose was not achieved. Results: In vivo drug biodistribution demonstrated that intracranial concentrations of TMZ increased threefold compared with orally delivered TMZ. In a rodent glioma model, animals treated with a single TMZ polymer (50% w/w) had a median survival of 28 days (P <0.001 vs. controls, P <0.001 vs. oral treatment), whereas animals treated with oral TMZ had a median survival of 22 days compared to control animals (median survival of 13 days). Animals treated with two TMZ polymers (50% w/w) had a median survival of 92 days (P <0.001 vs. controls, P <0.001 vs. oral treatment). The percentage of long-term survivors (LTS) for groups receiving intracranial TMZ ranged from 25 to 37.5%; there were no LTS with oral TMZ treatment. Animals treated with radiation therapy (XRT) and intracranial TMZ (median survival not reached, LTS = 87.5%) demonstrated improved survival compared to those with intracranial TMZ alone (median survival, 41 days; LTS = 37.5%), or oral TMZ and XRT (median survival, 43 days, LTS = 38.9%). Conclusions: The survival of tumor-bearing animals was improved with local delivery of TMZ compared with systemic administration. XRT in combination with intracranial TMZ did not cause additional toxicity and prolonged the survival even further.

AB - Purpose: Dose-limiting adverse effects of thrombocytopenia and leukopenia prevent augmentation of current temozolomide (TMZ) dosing protocols; therefore, we hypothesized that the direct intracranial delivery of TMZ would lead to improved efficacy in an animal model of malignant glioma in an animal model. Methods: Temozolomide was incorporated into biodegradable polymers and the active drug was released over 80 h. Intracranial toxicity was assessed in F344 rats and a maximally tolerated dose was not achieved. Results: In vivo drug biodistribution demonstrated that intracranial concentrations of TMZ increased threefold compared with orally delivered TMZ. In a rodent glioma model, animals treated with a single TMZ polymer (50% w/w) had a median survival of 28 days (P <0.001 vs. controls, P <0.001 vs. oral treatment), whereas animals treated with oral TMZ had a median survival of 22 days compared to control animals (median survival of 13 days). Animals treated with two TMZ polymers (50% w/w) had a median survival of 92 days (P <0.001 vs. controls, P <0.001 vs. oral treatment). The percentage of long-term survivors (LTS) for groups receiving intracranial TMZ ranged from 25 to 37.5%; there were no LTS with oral TMZ treatment. Animals treated with radiation therapy (XRT) and intracranial TMZ (median survival not reached, LTS = 87.5%) demonstrated improved survival compared to those with intracranial TMZ alone (median survival, 41 days; LTS = 37.5%), or oral TMZ and XRT (median survival, 43 days, LTS = 38.9%). Conclusions: The survival of tumor-bearing animals was improved with local delivery of TMZ compared with systemic administration. XRT in combination with intracranial TMZ did not cause additional toxicity and prolonged the survival even further.

KW - 9L gliosarcoma

KW - Local delivery

KW - Polymer

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=34547838615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547838615&partnerID=8YFLogxK

U2 - 10.1007/s00280-006-0407-2

DO - 10.1007/s00280-006-0407-2

M3 - Article

C2 - 17256133

AN - SCOPUS:34547838615

VL - 60

SP - 643

EP - 650

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -